Amphotericin B for Injection, USP [package insert]. Big Flats, NY: X-GEN Pharmaceuticals, Inc; 2010.
4.
GoodwinSDClearyJDWalawanderCATaylorJWGraselaTHJr.Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis. 1995;20:755-761. doi:10.1093/clinids/20.4.755
5.
RodenMMNelsonLDKnudsenTA, et al. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin Infect Dis. 2003;36:1213-1220. doi:10.1086/374553
6.
FarmakiotisDTverdekFPKontoyiannisDP.The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B. Clin Infect Dis. 2013;56:701-703. doi:10.1093/cid/cis972
7.
WingardJRWhiteMHAnaissieE, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31:1155-1163. doi:10.1086/317451
8.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:10.1038/clpt.1981.154
